Related Experiment Video
Updated: May 22, 2026
07:29
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
[Chemoradiotherapy for anal squamous cell carcinoma]
Harunobu Sato1, Koutarou Maeda, Hidetoshi Kobayashi
1Department of Surgery, Fujita Health University, Toyoake, Aichi, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|May 16, 2012
Summary
Local excision is recommended for early-stage anal margin cancers. For advanced stages, chemoradiotherapy with mitomycin C and 5-FU, or cisplatin for metastatic disease, is standard care.
Area of Science:
- Oncology
- Gastroenterology
- Radiation Oncology
Context:
- Current guidelines recommend local excision for T1, N0, well-differentiated anal margin cancers.
- Concurrent chemoradiotherapy is the standard for other stages of nonmetastatic anal margin and anal canal cancer.
- Abdominoperineal resection is reserved for recurrent or residual disease post-chemoradiotherapy.
Purpose:
- To summarize the recommended treatment algorithms for anal margin and anal canal cancers based on staging and differentiation.
- To outline the primary treatment modalities including surgery, chemotherapy, and radiation therapy.
- To highlight the role of chemoradiotherapy in managing advanced or recurrent anal cancers.
Summary:
- For early-stage anal margin cancer (T1, N0, well-differentiated), local excision with adequate margin is primary treatment.
- Concurrent chemotherapy (mitomycin C and 5-FU) with radiation (45-59 Gy) is recommended for other nonmetastatic anal cancers.
- Chemotherapy (cisplatin and 5-FU) is indicated for distant metastases, with radiotherapy for symptomatic local control. Abdominoperineal resection is used for local recurrence or post-chemoradiotherapy residual disease.
Impact:
- Provides a clear treatment pathway for anal cancers, aligning with National Comprehensive Cancer Network guidelines.
- Emphasizes the increasing role of chemoradiotherapy, particularly for anal squamous cell carcinoma.
- Identifies future research directions, including optimizing cisplatin-based chemoradiotherapy and developing oral anticancer agents.
Related Concept Videos
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...